Cargando…
Peptide Receptor Radionuclide Therapy (PRRT) with (177)Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
SIMPLE SUMMARY: Patients suffering from disseminated, progressive, neuroendocrine neoplasms with a sufficient amount of somatostatin receptors and good kidney function can be treated with radioactive hormone-like molecules to prolong their life. In this study, the radioactivity in one tumor per pati...
Autores principales: | Jahn, Ulrika, Ilan, Ezgi, Sandström, Mattias, Lubberink, Mark, Garske-Román, Ulrike, Sundin, Anders |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956792/ https://www.ncbi.nlm.nih.gov/pubmed/33668887 http://dx.doi.org/10.3390/cancers13050962 |
Ejemplares similares
-
Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression
por: Jahn, Ulrika, et al.
Publicado: (2023) -
Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours
por: Sandström, Mattias, et al.
Publicado: (2015) -
Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
por: Sandström, Mattias, et al.
Publicado: (2020) -
Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with (177)Lu-DOTATATE
por: Vyakaranam, Achyut Ram, et al.
Publicado: (2019) -
Tumor Contrast-Enhancement for Monitoring of PRRT (177)Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients
por: Pettersson, Olof, et al.
Publicado: (2020)